TEST:

Prosigna® Breast Risk of Recurrence (ROR) Test

Ranks and word2vec embeddings derived from relative gene expression order enable machine learning models to robustly classify breast cancer subtypes. They address technical variability by reducing dependence on cohort-wide normalization, thereby supporting reliable subtype classification in diverse clinical settings.

P2, N=40, Recruiting, Icahn School of Medicine at Mount Sinai | Trial primary completion date: Dec 2026 --> Dec 2027

P=N/A, N=750, Completed, Novartis Pharmaceuticals

P3, N=1556, Suspended, Alliance for Clinical Trials in Oncology | N=1156 --> 1556

PDZK1 functions as a regulator of HER2 stability and may serve as a potential biomarker and therapeutic target in HER2-positive breast cancer. Pharmacological upregulation of PDZK1 may represent a promising combinatorial therapeutic strategy for overcoming therapeutic resistance in breast cancer.

Multi-platform and multi-omics profiling in this large unique cohort of longitudinal TNBC samples revealed distinct patterns of expression and dynamic changes of key biomarkers of interest for targeted therapies. Given variability with manual IHC scoring, improved methods for quantification of expression may help optimize treatment selection in an individualized manner.

We established a low-ITH subtyping framework that overcomes the limitations of single-biopsy-based molecular typing. Our findings offer a novel strategy to enhance the precision of breast cancer management.

"On the heels of the landmark OPTIMA trial readout presented at the ASCO Annual Meeting, Veracyte...today announced the U.S. commercial launch of the Prosigna® Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer. The Prosigna test determines a patient’s ROR score and estimates the 10-year probability of distant recurrence, providing prognostic insight into how a patient’s cancer may behave over time. These insights also help guide treatment decisions, including predicting whether high risk patients are likely to benefit from chemotherapy or may safely achieve optimal outcomes with endocrine therapy alone, enabling clinicians to make personalized care plans for their patients. The Prosigna test will be available to order starting June 8, 2026."

This study uncovers environmental mutagenesis as a previously overlooked but critical driver of luminal breast cancer heterogeneity in East Asian patients. We establish a proteogenomics-transformative scheme to guide risk stratification and subtype-specific vulnerabilities, offering a precision oncology strategy for early-stage East Asian breast cancer management.

A lineage-aware GAN framework yields compact, interpretable signatures that capture ecosystem-level biology (immune activity, ECM remodeling, epithelial plasticity) and can be projected into TCGA-BRCA for subtype-aware prognostic stratification in breast cancer.

The cuproptosis-based risk score model effectively predicts NAC response and may guide personalized treatment in BC. It also reveals the relevance of cuproptosis-related genes in immune modulation and chemotherapy sensitivity.

''Veracyte, Inc...announced today results from the independent OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) trial, led by University College London (UCL). The results, which will be presented at the ASCO Annual Meeting, conclude that the Prosigna® Breast Risk of Recurrence (ROR) test safely guides adjuvant chemotherapy decisions in patients with early-stage, ER-positive HER2-negative breast cancer.''